Case of drug-induced interstitial lung disease secondary to adalimumab

We report a rare case of drug-induced intestinal lung disease (ILD) secondary to adalimumab, a tumour necrosis factor alpha-receptor blocker. A 52-year-old smoker with ankylosing spondylitis, treated with adalimumab, presented with progressive breathlessness. A high resolution CT chest demonstrated...

Full description

Saved in:
Bibliographic Details
Published in:BMJ Case Rep
Main Authors: Alaee, Seema, Jones, Quentin
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2018
Subjects:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5965751/
https://ncbi.nlm.nih.gov/pubmed/29764848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2018-224375
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items